(More on the Xtandi case here: https://www.keionline.org/xtandi2021) Astellas has issued a statement, dated February 9, 2022, on the Bayh-Dole Act and the petition to exercise march-in and government use rights in the prostate cancer drug Xtandi. It was brought to… Continue Reading
In a January 31, 2022 letter to Drew Hirshfeld, the Commissioner for Patents for the USPTO, and Janet Woodcock, the Acting Commissioner of the FDA, Senator Thom Tillis provides extensive criticism of the empirical work of the group I-MAK and… Continue Reading
Comments of Knowledge Ecology International (KEI) 2022 Special 301 Review: Docket (USTR-2021-0021) January 31, 2022 1. The public comment process should provide the public with the opportunity to respond to industry submissions. The Special 301 submissions are primarily from rights… Continue Reading
Update: Video recording of the press briefing available here: https://www.youtube.com/watch?v=KwqUl7NLMXo) December 15th 10AM – Briefing on Xtandi March-in Request Supporters of the march-in petition to lower the cost of the prostate cancer drug Xtandi will host a virtual press conference… Continue Reading
USTR-AmbTai-Bilateral-Plurilateal-agreements-3Dec2021 December 3, 2021 Ambassador Katherine Tai Office of the United States Trade Representative Washington, DC Dear Ambassador Tai, On November 18, 2021, Knowledge Ecology International (KEI) provided comments to USTR on three issues that were important for any WTO… Continue Reading
On October 1, 2001, the World Trade Organization (WTO) issued a “Report of the Working Party on the Accession of China.” The 180 page document (WT/ACC/CHN/49) included a discussion of the views of “some members” of the WTO regarding the… Continue Reading
KEI sent this letter to USTR today regarding the TRIPS Waiver negotiations. Highlights what we think are the three most important issues. KEI-USTR-TRIPS-waiver-Priorities-18nov2021 November 18, 2021 Ambassador Katherine Tai Office of the United States Trade Representative Washington, DC Dear Ambassador… Continue Reading
On November 16, 2021, Pfizer and the Medicines Patent Pool (MPP) announced at voluntary license to patented inventions and know-how to manufacture a two drug combination to treat COVID-19. The MPP announcement is here and here. Additional comments on the… Continue Reading
November 10, 2021 Andrew Burke, Ph.D. Senior Technology Transfer Manager, NCI Technology Transfer Center, Email: andy.burke@nih.gov. Re: Prospective Grant of an Exclusive Patent License: Development and Commercialization of CRISPR-Engineered T Cell Therapies for the Treatment of Cancer to Neogene Therapeutics… Continue Reading
(For more resources, please see our page on molnupiravir.) According to Brook Baker, these are the countries included in the Merck voluntary license to generic suppliers Afghanistan, Algeria, Angola, Bangladesh, Belize, Benin, Bhutan, Bolivia, Botswana, Burkina Faso, Burundi, Cambodia, Cameroon,… Continue Reading